Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership
By Labmedica International staff writers
28 Oct 2020
The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory settings for rapidly detecting COVID-19.
Providing clear and concise results, direct at the point of care, the collaborative approach of Randox and Bosch Healthcare not only allows patients to take the recommended safety precautions without delay, but also provides solutions to both analyze and differentiate COVID-19 from other viral respiratory diseases. Their combined efforts have resulted in the launch of the Vivlaytic, an all in one solution for molecular diagnostics consolidating nucleic acid extraction, polymerase chain reaction (PCR) and detection in one small platform. These efforts reflect the global partnership between the companies who are working together to deliver world-class diagnostic solutions, harnessing the power of innovation to improve health worldwide, and providing an all-in-one approach for minimizing the spread of COVID-19 globally.
The Viral Respiratory Infection array (VRI) rapidly detects the SARS-CoV-2 virus that causes COVID-19 while simultaneously differentiating between nine other respiratory diseases, in less than two and a half hours. Randox, Bosch Healthcare and R-Biopharm also offer various analysis strategies to detect SARS-CoV-2. Capable of providing reliable results in just 39 minutes, with a sensitivity of 98% and specificity of 100%, the Vivalytic SARS-CoV-2 rapid test is currently among the fastest PCR tests worldwide.
Randox and Bosch Healthcare offer a range of different testing strategies, including the upcoming SARS-CoV-2 Pooling test. The SARS-CoV-2 Pooling test is a rapid solution for the detection of SARS-CoV-2, offering an accelerated decentralized testing approach for effectively and efficiently monitoring and detecting viral infection from the onset. The solution is capable of detecting SARS-CoV-2 from up to five pooled samples simultaneously with a capacity for processing more than 160 patient samples a day. Sample pooling allows more people to be tested quickly using fewer testing resources. The pooling can be done at the level of a ward, medical specialty, social bubble, or a group of colleagues. It also has potential for use in other settings, such as pre-operative screening, schools & universities, prisons, nursing homes, primary care, and large workplaces.